vs
Side-by-side financial comparison of Orchid Island Capital, Inc. (ORC) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $38.5M, roughly 2.0× Orchid Island Capital, Inc.). On growth, Orchid Island Capital, Inc. posted the faster year-over-year revenue change (372.6% vs 27.7%). Over the past eight quarters, Orchid Island Capital, Inc.'s revenue compounded faster (301.6% CAGR vs 31.3%).
Orchid Island Capital, Inc. is a U.S.-based specialty finance company operating as a real estate investment trust. It primarily invests in residential mortgage-backed securities, including agency and non-agency products, targeting consistent risk-adjusted returns for its investors across U.S. fixed income markets.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
ORC vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.5M | $75.5M |
| Net Profit | $103.4M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 268.7% | — |
| Revenue YoY | 372.6% | 27.7% |
| Net Profit YoY | 1764.9% | — |
| EPS (diluted) | — | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.5M | $75.5M | ||
| Q3 25 | $26.9M | $54.5M | ||
| Q2 25 | $23.2M | $52.4M | ||
| Q1 25 | $19.7M | $46.0M | ||
| Q4 24 | — | $59.1M | ||
| Q3 24 | $340.0K | $80.5M | ||
| Q2 24 | $-697.0K | $47.1M | ||
| Q1 24 | $-2.5M | $43.8M |
| Q4 25 | $103.4M | — | ||
| Q3 25 | $72.1M | $8.8M | ||
| Q2 25 | $-33.6M | $5.9M | ||
| Q1 25 | $17.1M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $17.3M | $20.3M | ||
| Q2 24 | $-5.0M | $-4.5M | ||
| Q1 24 | $19.8M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | — | 22.7% | ||
| Q3 25 | — | 17.6% | ||
| Q2 25 | — | 12.7% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | -4.6% | ||
| Q1 24 | — | -5.3% |
| Q4 25 | 268.7% | — | ||
| Q3 25 | 267.8% | 16.2% | ||
| Q2 25 | -145.0% | 11.2% | ||
| Q1 25 | 86.9% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 5094.1% | 25.2% | ||
| Q2 24 | 714.3% | -9.6% | ||
| Q1 24 | -794.2% | -11.0% |
| Q4 25 | — | $0.26 | ||
| Q3 25 | — | $0.17 | ||
| Q2 25 | — | $0.12 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | — | $0.41 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $665.9M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $1.4B | $130.3M |
| Total Assets | $11.7B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $665.9M | $97.5M | ||
| Q3 25 | $583.9M | $94.4M | ||
| Q2 25 | $440.8M | $96.0M | ||
| Q1 25 | $396.4M | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | $322.1M | $96.7M | ||
| Q2 24 | $241.0M | $96.8M | ||
| Q1 24 | $190.4M | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $1.4B | $130.3M | ||
| Q3 25 | $1.1B | $115.3M | ||
| Q2 25 | $912.0M | $104.7M | ||
| Q1 25 | $855.9M | $97.1M | ||
| Q4 24 | — | $92.1M | ||
| Q3 24 | $656.0M | $71.1M | ||
| Q2 24 | $555.9M | $48.5M | ||
| Q1 24 | $481.6M | $51.0M |
| Q4 25 | $11.7B | $216.3M | ||
| Q3 25 | $9.1B | $202.9M | ||
| Q2 25 | $7.6B | $194.9M | ||
| Q1 25 | $7.3B | $196.2M | ||
| Q4 24 | — | $213.3M | ||
| Q3 24 | $5.9B | $220.7M | ||
| Q2 24 | $4.9B | $205.0M | ||
| Q1 24 | $4.2B | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.4M | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 1.16× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.4M | $14.4M | ||
| Q3 25 | $28.0M | $9.7M | ||
| Q2 25 | $18.4M | $14.1M | ||
| Q1 25 | $25.8M | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | $-14.8M | $11.0M | ||
| Q2 24 | $19.3M | $1.0M | ||
| Q1 24 | $45.0M | $11.2M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | 1.16× | — | ||
| Q3 25 | 0.39× | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | 1.51× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.86× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
